Kazushige Wakuda

2.5k citations

117 papers · 1.6k indexed · h-index 24

Oncology top 2%
- Lung Cancer Research Studies 53
- Cancer Immunotherapy and Biomarkers 22
- Colorectal Cancer Treatments and Studies 14
Pulmonary and Respiratory Medicine top 2%
- Lung Cancer Treatments and Mutations 68
- Lung Cancer Diagnosis and Treatment 24
- Brain Metastases and Treatment 8
Geriatrics and Gerontology top 5%
Cancer Research top 10%
- Cancer Genomics and Diagnostics 11
Physiology top 10%
Epidemiology
- Neuroendocrine Tumor Research Advances 20

Co-authors: Hirotsugu Kenmotsu Toshiaki Takahashi Haruyasu Murakami Akira Ono Tateaki Naito Masahiro Endo Shota Omori Keita Mori
Cited by: Oncology Pulmonary and Respiratory Medicine Geriatrics and Gerontology
Journals: Journal of Clinical Oncology (15 papers)SHILAP Revista de lepidopterología (1 paper)PLoS ONE (1 paper)
Partner nations: Japan United States United Kingdom

In The Last Decade

Kazushige Wakuda

109 papers receiving 1.6k citations

Peers

Countries citing papers authored by Kazushige Wakuda

Since Specialization

Citations

This map shows the geographic impact of Kazushige Wakuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kazushige Wakuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kazushige Wakuda more than expected).

Fields of papers citing papers by Kazushige Wakuda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kazushige Wakuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kazushige Wakuda. The network helps show where Kazushige Wakuda may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kazushige Wakuda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kazushige Wakuda Line = papers co-authored together Kazushige Wakuda links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer Thoracic Cancer ·Michitoshi Yabe,Tateaki Naito,Suguru Matsuda,Meiko Morita,Motoki Sekikawa,Keita Miura,Hiroaki Kodama,Toshiya Fujisaki,Nobuaki Mamesaya,Haruki Kobayashi,Ryo Ko,Kazushige Wakuda,Akira Ono,Hirotsugu Kenmotsu,Haruyasu Murakami,Toshiaki Takahashi	2025	1
2	8O First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohorts 2 and 4) ESMO Open ·Kristof Cuppens,K. Papadopoulos,Makoto Nishio,Kazushige Wakuda,Martin Gutierrez,Shuji Murakami,Giselle Dutcher,Izabela Chmielewska,T-Y. Yang,C-H. Chiu,Ewa Kalinka‐Warzocha,A. Spira,V. Haddad,Mariana Hinzmann,Xingyi Shi,Saiama N. Waqar	2025	1
3	Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study Thoracic Cancer ·Kosei Doshita,Tateaki Naito,Suguru Matsuda,Meiko Morita,Motoki Sekikawa,Keita Miura,Hiroaki Kodama,Michitoshi Yabe,Noboru Morikawa,Yuko Iida,Nobuaki Mamesaya,Haruki Kobayashi,Ryo Ko,Kazushige Wakuda,Akira Ono,Haruyasu Murakami,Hirotsugu Kenmotsu,Toshiaki Takahashi	2024	2
4	Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma Scientific Reports ·Yuko Iida,Kazushige Wakuda,Hirotsugu Kenmotsu,Kosei Doshita,Hiroaki Kodama,Naoya Nishioka,Eriko Miyawaki,Taichi Miyawaki,Nobuaki Mamesaya,Haruki Kobayashi,Shota Omori,Ryo Ko,Akira Ono,Tateaki Naito,Haruyasu Murakami,Takashi Sugino,Yasuhiro Gon,Toshiaki Takahashi	2024	1
5	Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer Thoracic Cancer ·Yuko Iida,Kazushige Wakuda,Takuya Kawata,Meiko Morita,Motoki Sekikawa,Kosei Doshita,Michitoshi Yabe,Hiroaki Kodama,Keita Miura,Noboru Morikawa,Nobuaki Mamesaya,Haruki Kobayashi,Ryo Ko,Akira Ono,Hirotsugu Kenmotsu,Tateaki Naito,Haruyasu Murakami,Yasuhiro Gon,Toshiaki Takahashi	2024	2
6	Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L) JTO Clinical and Research Reports ·Motoko Tachihara,Akito Hata,Takaaki Tokito,Satoshi Hara,Hideaki Okada,Satoru Miura,Yuki Sato,Eriko Tabata,Hiroshi Watanabe,Yusuke Takayama,Ryo Toyozawa,Keiichi Ota,Kazushige Wakuda,Atsushi Nakamura,Mototsugu Shimokawa,Nobuyuki Yamamoto,Kazuhiko Nakagawa	2023	0
7	Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer Thoracic Cancer ·Motoki Sekikawa,Haruyasu Murakami,Meiko Morita,Kosei Doshita,Keita Miura,Hiroaki Kodama,Noboru Morikawa,Yuko Iida,Nobuaki Mamesaya,Haruki Kobayashi,Ryo Ko,Kazushige Wakuda,Akira Ono,Hirotsugu Kenmotsu,Tateaki Naito,Hirofumi Chiba,Toshiaki Takahashi	2023	1
8	Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients Cancer Chemotherapy and Pharmacology ·Hirotsugu Kenmotsu,Chiyo K. Imamura,Takahisa Kawamura,Takuya Oyakawa,Shota Omori,Kazuhisa Nakashima,Kazushige Wakuda,Akira Ono,Tetsuhiko Taira,Tateaki Naito,Haruyasu Murakami,Nobuyuki Yamamoto,Toshiaki Takahashi,Yusuke Tanigawara	2022	3
9	Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer Thoracic Cancer ·Naoya Nishioka,Tateaki Naito,Taichi Miyawaki,Michitoshi Yabe,Kosei Doshita,Hiroaki Kodama,Eriko Miyawaki,Yuko Iida,Nobuaki Mamesaya,Haruki Kobayashi,Shota Omori,Ryo Ko,Kazushige Wakuda,Akira Ono,Hirotsugu Kenmotsu,Haruyasu Murakami,Koichi Takayama,Toshiaki Takahashi	2022	12
10	Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy Advances in Radiation Oncology ·Kosei Doshita,Yuya Tabuchi,Hirotsugu Kenmotsu,Shota Omori,Takanori Kawabata,Hiroaki Kodama,Naoya Nishioka,Eriko Miyawaki,Yuko Iida,Nobuaki Mamesaya,Haruki Kobayashi,Ryo Ko,Kazushige Wakuda,Akira Ono,Tateaki Naito,Haruyasu Murakami,Keita Mori,Hideyuki Harada,Takeshi Kaneko,Toshiaki Takahashi	2022	4
11	Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer Cancer Medicine ·Taichi Miyawaki,Hirotsugu Kenmotsu,Kosei Doshita,Hiroaki Kodama,Naoya Nishioka,Yuko Iida,Eriko Miyawaki,Nobuaki Mamesaya,Haruki Kobayashi,Shota Omori,Ryo Ko,Kazushige Wakuda,Akira Ono,Tateaki Naito,Haruyasu Murakami,Keita Mori,Hideyuki Harada,Masahiro Endo,Kazuhisa Takahashi,Toshiaki Takahashi	2022	4
12	Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation Cancer Medicine ·Hiroaki Kodama,Hirotsugu Kenmotsu,Takanori Kawabata,Akifumi Notsu,Michitoshi Yabe,Naoya Nishioka,Eriko Miyawaki,Taichi Miyawaki,Nobuaki Mamesaya,Haruki Kobayashi,Shota Omori,Kazushige Wakuda,Akira Ono,Tateaki Naito,Haruyasu Murakami,Toshiaki Takahashi	2021	4
13	A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903 ESMO Open ·Kentaro Ito,Masahiro Morise,Kazushige Wakuda,Osamu Hataji,Tadasuke Shimokawaji,Kosuke Takahashi,Naoki Furuya,Yoshihiro Takeyama,Yasuhiro Gotô,Tetsuya Abe,Terufumi Kato,Sachiko Ozone,Satoshi Ikeda,Yoshihito Kogure,Toshihiko Yokoyama,M. Kimura,Hiroshige Yoshioka,Kenta Murotani,Masashi Kondo,Hideo Saka	2021	33
14	Prospective evaluation and refinement of an S‐1 dosage formula based on renal function for clinical application Cancer Science ·Masashi Takeuchi,Chiyo K. Imamura,Eisuke Booka,Hiroya Takeuchi,Takuro Mizukami,Takeshi Kawakami,Taro Funakoshi,Kazushige Wakuda,Yu Aoki,Yasuo Hamamoto,Minoru Kitago,Hirofumi Kawakubo,Narikazu Boku,Yusuke Tanigawara,Yuko Kitagawa	2020	3
15	Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy Cancer Science ·Taichi Miyawaki,Kazushige Wakuda,Hirotsugu Kenmotsu,Eriko Miyawaki,Nobuaki Mamesaya,Haruki Kobayashi,Shota Omori,Akira Ono,Tateaki Naito,Haruyasu Murakami,Akifumi Notsu,Keita Mori,Hideyuki Harada,Masahiro Endo,Yasuhisa Ohde,Kazuhisa Takahashi,Toshiaki Takahashi	2020	8
16	Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer Cancer Medicine ·Naoya Nishioka,Tateaki Naito,Akifumi Notsu,Keita Mori,Hiroaki Kodama,Eriko Miyawaki,Taichi Miyawaki,Nobuaki Mamesaya,Haruki Kobayashi,Shota Omori,Kazushige Wakuda,Akira Ono,Hirotsugu Kenmotsu,Haruyasu Murakami,Koichi Takayama,Toshiaki Takahashi	2020	30
17	Platinum Combination Chemotherapy Is Poorly Tolerated in Malnourished Advanced Lung Cancer Patients with Poor Performance Status Nutrition and Cancer ·Takayuki Fujio,Kazuhisa Nakashima,Tateaki Naito,Haruki Kobayashi,Shota Omori,Kazushige Wakuda,Akira Ono,Hirotsugu Kenmotsu,Haruyasu Murakami,Toshiaki Takahashi	2019	7
18	Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer Lung Cancer ·Akira Ono,Mitsuhiro Isaka,Masakuni Serizawa,Katsuhiro Omae,Hideaki Kojima,Kazuhisa Nakashima,Shota Omori,Kazushige Wakuda,Hirotsugu Kenmotsu,Tateaki Naito,Haruyasu Murakami,Kenichi Urakami,Takeshi Nagashima,Takashi Sugino,Masatoshi Kusuhara,Toshiaki Takahashi,Ken Yamaguchi,Yasuhisa Ohde	2018	10
19	ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease Lung Cancer ·Haruki Kobayashi,Tateaki Naito,Katsuhiro Omae,Shota Omori,Kazuhisa Nakashima,Kazushige Wakuda,Akira Ono,Hirotsugu Kenmotsu,Haruyasu Murakami,Masahiro Endo,Toshiaki Takahashi	2018	13
20	Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter Cancer Science ·Masaru Watanabe,Hirotsugu Kenmotsu,Ryo Ko,Kazushige Wakuda,Akira Ono,Hisao Imai,Tetsuhiko Taira,Tateaki Naito,Haruyasu Murakami,Masato Abe,Masahiro Endo,Takashi Nakajima,Yasuhiro Koh,Toshiaki Takahashi	2018	32

About Kazushige Wakuda

Kazushige Wakuda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 117 papers that have together received 1.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (68 papers), Lung Cancer Research Studies (53 papers), Lung Cancer Diagnosis and Treatment (24 papers), Cancer Immunotherapy and Biomarkers (22 papers), Neuroendocrine Tumor Research Advances (20 papers), Colorectal Cancer Treatments and Studies (14 papers), Cancer Genomics and Diagnostics (11 papers) and Brain Metastases and Treatment (8 papers). The work is most often cited by research in Oncology (1.1k citations), Pulmonary and Respiratory Medicine (1.0k citations) and Geriatrics and Gerontology (69 citations). Kazushige Wakuda has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Hirotsugu Kenmotsu, Toshiaki Takahashi, Haruyasu Murakami, Akira Ono, Tateaki Naito, Masahiro Endo, Shota Omori, Keita Mori, Haruki Kobayashi and Tetsuhiko Taira. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact